News & Updates

The role of oral antivirals in COVID-19 treatment: Who, when, and how?

Though most countries have eased pandemic restrictions, there is no room for complacency in managing COVID-19, which continues to cause significant morbidity and mortality.

At a recent symposium, esteemed experts Dr Roger Paredes, Head of Department of Infectious Diseases at the Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, and Dr Nicola Petrosillo, Head of the Infection Prevention and Control and Infectious Disease Service at University Hospital Campus Bio-Medico, Rome, Italy, gave global perspectives on the continuing unmet needs in the COVID-19 outpatient landscape and discussed the role of antiviral treatment options in patients at risk of progressing to severe COVID-19. Dr Petrick Periyasamy, Head of Infectious Diseases Unit, Medical Department, UKM Medical Centre, Kuala Lumpur, Malaysia, chaired the session.

SGLT2 inhibitors cut obstructive airway disease risk in type 2 diabetes

Treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors appears to have the added benefit of reducing the incidence of obstructive airway disease (OAD) in Asian patients with type 2 diabetes (T2D), as shown in a study from Hong Kong.

Robotic-assisted bronchoscopy on par with biopsy for nodules diagnosis

Robotic-assisted bronchoscopy (RAB) appears to be as reliable as computed tomography-guided transthoracic biopsy (CTTB) in sampling pulmonary nodules with similar or reduced complications, a study has shown.

Original New Drug Application Approvals by US FDA (01-15 January 2023)

New drug applications approved by US FDA as of 01-15 January 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Are parents equipped to manage their kid’s allergies?

Despite the increasing prevalence of childhood allergies, most parents are unprepared to manage them, a two-part study has shown.